Victory Park Capital reports 7.4% passive stake in Unigene

By E. Janene Geiss

Philadelphia, Oct. 20 - Victory Park Capital Advisors, LLC reported a 7.4% stake in Unigene Laboratories, Inc. as of Oct. 9, according to an SC 13G filing with the Securities and Exchange Commission.

The passive holding represents 6,632,314 shares of common stock.

Fairfield, N.J.-based Unigene is a biopharmaceutical company focusing on the oral and nasal delivery of peptide-based drugs.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.